Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Recruiting now · Phase 1
Conditions studied: Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis), SCI - Spinal Cord Injury, Spinal Radiculopathy
In brief
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Key facts
- Study ID
- NCT06999434
- Run by
- Yale University
- People needed
- 105
- Starts
- 2025-05-05
- Expected to finish
- 2030-05-05
- Last updated by the study team
- 2025-05-31
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.
Where it is running
- Yale University PET Center — New Haven, Connecticut, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.